These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16613559)

  • 1. Modified recombinant allergens for safer immunotherapy.
    Ferreira F; Briza P; Inführ D; Schmidt G; Wallner M; Wopfner N; Thalhamer J; Achatz G
    Inflamm Allergy Drug Targets; 2006 Jan; 5(1):5-14. PubMed ID: 16613559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
    Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
    J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
    J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen.
    Son DY; Scheurer S; Hoffmann A; Haustein D; Vieths S
    Eur J Nutr; 1999 Aug; 38(4):201-15. PubMed ID: 10502033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific immunotherapy : clinical experience with recombinant molecular major allergens and hypoallergenic variants].
    Schendzielorz P; Klimek L
    HNO; 2013 Oct; 61(10):834-42. PubMed ID: 23913191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic engineering of pollen allergens for hayfever immunotherapy.
    Bhalla PL
    Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.
    Tighe H; Takabayashi K; Schwartz D; Van Nest G; Tuck S; Eiden JJ; Kagey-Sobotka A; Creticos PS; Lichtenstein LM; Spiegelberg HL; Raz E
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):124-34. PubMed ID: 10887315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic engineering of allergens: future therapeutic products.
    Ferreira F; Wallner M; Breiteneder H; Hartl A; Thalhamer J; Ebner C
    Int Arch Allergy Immunol; 2002 Jul; 128(3):171-8. PubMed ID: 12119498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.
    Tscheppe A; Breiteneder H
    Int Arch Allergy Immunol; 2017; 172(4):187-202. PubMed ID: 28467993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy.
    Ferreira F; Ebner C; Kramer B; Casari G; Briza P; Kungl AJ; Grimm R; Jahn-Schmid B; Breiteneder H; Kraft D; Breitenbach M; Rheinberger HJ; Scheiner O
    FASEB J; 1998 Feb; 12(2):231-42. PubMed ID: 9472988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies for allergen immunotherapy.
    Carnés J; Robinson DS
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jun; 2(2):92-101. PubMed ID: 19075996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and modifications of allergens for improving specific immunotherapy.
    Velickovic TC; Jankov RM
    Inflamm Allergy Drug Targets; 2008 Dec; 7(4):270-8. PubMed ID: 19075791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights of Novel Vaccination Strategies in Allergen Immunotherapy.
    Komlósi ZI; Kovács N; Sokolowska M; van de Veen W; Akdis M; Akdis CA
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):15-24. PubMed ID: 31761116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
    Valenta R; Linhart B; Swoboda I; Niederberger V
    Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies.
    Kraft D; Ferreira F; Vrtala S; Breiteneder H; Ebner C; Valenta R; Susani M; Breitenbach M; Scheiner O
    Int Arch Allergy Immunol; 1999; 118(2-4):171-6. PubMed ID: 10224369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.
    Creticos PS; Lichtenstein LM
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):304-12; discussion 312-3. PubMed ID: 15119051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.